anifrolumab   Click here for help

GtoPdb Ligand ID: 8258

Synonyms: anifrolumab-fnia | MDX-1333 | MEDI-546 | Saphnelo®
Approved drug Immunopharmacology Ligand
anifrolumab is an approved drug (FDA (2021))
Compound class: Antibody
Comment: Anifrolumab is a monoclonal antibody targeting IFNAR1 (the receptor for α, β and ω interferons), that was developed by the MedImmune subsidiary of AstraZeneca as a treatment for systemic lupus erythematosus (SLE).
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. [3]. Sequence BLAST using the heavy and light chain variable regions of anifrolumab provides 100% matches to sequences that are claimed in patent US7662381 [3]. The sequence matches identify anifrolumab as clone 11E2 in the patent.
Click here for help
Classification Click here for help
Compound class Antibody
Approved drug? Yes (FDA (2021))
International Nonproprietary Names Click here for help
INN number INN
9800 anifrolumab
Synonyms Click here for help
anifrolumab-fnia | MDX-1333 | MEDI-546 | Saphnelo®
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 474
Other databases
GtoPdb PubChem SID 249565938
Search PubMed clinical trials anifrolumab
Search PubMed titles anifrolumab
Search PubMed titles/abstracts anifrolumab
Wikipedia Anifrolumab